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Abstract
Human induced pluripotent stem cell (hiPSC)-derived blood-brain barrier (BBB) 
models established to date lack expression of key adhesion molecules involved in 
immune cell migration across the BBB in vivo. Here, we introduce the extended 
endothelial cell culture method (EECM), which differentiates hiPSC-derived en-
dothelial progenitor cells to brain microvascular endothelial cell (BMEC)-like cells 
with good barrier properties and mature tight junctions. Importantly, EECM-BMEC-
like cells exhibited constitutive cell surface expression of ICAM-1, ICAM-2, and 
E-selectin. Pro-inflammatory cytokine stimulation increased the cell surface expres-
sion of ICAM-1 and induced cell surface expression of P-selectin and VCAM-1. 
Co-culture of EECM-BMEC-like cells with hiPSC-derived smooth muscle-like cells 
or their conditioned medium further increased the induction of VCAM-1. Functional 
expression of endothelial ICAM-1 and VCAM-1 was confirmed by T-cell interaction 
with EECM-BMEC-like cells. Taken together, we introduce the first hiPSC-derived 
BBB model that displays an adhesion molecule phenotype that is suitable for the 
study of immune cell interactions.
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1 |  INTRODUCTION
Under physiological conditions, the blood-brain barrier 
(BBB) maintains central nervous system (CNS) homeo-
stasis by protecting the CNS from the constantly changing 
milieu in the bloodstream. The BBB is established by brain 
microvascular endothelial cells (BMECs), which inhibit free 
paracellular diffusion of water-soluble molecules by complex 
tight junctions that connect the endothelial cells.1 Combined 
with their characteristically low pinocytotic activity and lack 
of fenestrations, which inhibit transcellular passage of mol-
ecules across the BBB, these features establish the physical 
barrier of the BBB.2 At the same time, the BBB establishes a 
functional barrier, in which the expression of specific trans-
porters and enzymes in BMECs ensures that nutrients pass 
into the CNS and toxic metabolites are removed from the 
CNS. In the absence of neuroinflammation, the BBB also 
limits immune cell trafficking to specific immune cell sub-
sets that ensure CNS immune surveillance.3 Importantly, the 
segments of the microvasculature mediating immune cell 
trafficking vs regulating transport of solutes are not identi-
cal; while solute transport is predominantly localized to CNS 
capillaries, immune cell trafficking occurs at the level of 
CNS postcapillary venules.4,5
Current knowledge about the cellular and molecular 
mechanisms mediating immune cell migration across the 
BBB during CNS immune surveillance and neuroinflamma-
tion have to a large degree been derived from animal models 
of neuroinflammatory diseases. These studies showed that 
the migration of immune cells across the BBB follows a mul-
tistep process that is regulated by the sequential interaction 
of different signaling and adhesion molecules on the BBB 
endothelium and the immune cells.4 Because of the unique 
tightness of this vascular bed, immune cell migration across 
the BBB is characterized by unique adaptations. These range 
from a predominant role of α4β1-integrin in mediating inter-
action of T cells with endothelial VCAM-16 to the extended 
crawling of T cells mediated by endothelial ICAM-1 and 
ICAM-2 against the direction of the blood flow in search of 
rare sites permissive for diapedesis across the BBB.7,8
There are some limitations when applying knowledge 
from animal models to humans. It has been observed that lev-
els of some adhesion molecules (eg, activated leukocyte cell 
adhesion molecule (ALCAM) or junctional adhesion mole-
cules (JAMs)) are different between rodents and human.9 As 
a result, there is a significant need for human BBB models 
that are suitable for the study of immune cell trafficking 
across the BBB. To this end, human brain endothelial cell 
lines (eg, hCMEC/D310) have been established allowing the 
study of barrier properties and immune cell trafficking under 
inflammatory conditions. Unfortunately, these BBB models 
often fail to establish complex tight junctions and barrier 
properties characterized by high transendothelial electrical 
resistance (TEER) and low permeability of soluble tracers.11 
Appropriate barrier properties are prerequisite for appropri-
ate modeling of the unique mechanisms involved in T-cell 
diapedesis across the BBB.12 Primary human brain micro-
vascular endothelial cells (hBMECs) have proven useful to 
study T-cell/BBB interactions; however, these cells are often 
not readily available to researchers12,13 and they come from 
non-autologous sources. Recent advances in stem cell tech-
nology have allowed derivation of hBMEC-like cells from 
various stem cell sources including human cord blood-de-
rived endothelial progenitors and human pluripotent stem 
cells (hPSCs).14,15 In particular, patient-sourced human in-
duced pluripotent stem cell (hiPSC)-derived BMEC-like 
cells uniquely enable the study of BBB dysfunction by pro-
viding a scalable and renewable source of BMEC-like cells. 
For immune cell studies, one could also envision combining 
hiPSC and autologous immune cells sourced from the same 
patient cohort. Human iPSC-derived in vitro models of the 
BBB have been established14,16–18 and proven useful for mod-
eling BBB dysfunction in inheritable neurological disorders 
in vitro.19–21
Presently available hiPSC-derived in vitro BBB models 
are well characterized with respect to their barrier prop-
erties and expression of BBB-specific transporters and 
efflux pumps14,16,17 and have proven useful for the study 
of barrier regulation, molecular transport, and brain drug 
delivery. However, much less is known about the immune 
phenotypes such as the expression and cytokine-induced 
upregulation of adhesion molecules in hiPSC-derived in 
vitro BBB models. These properties are extremely im-
portant when aiming to apply hiPSC-derived in vitro BBB 
models to study cerebrovascular pathologies involved in 
multiple sclerosis, stroke, or CNS infections, where im-
mune cell trafficking across the BBB critically contributes 
to disease pathogenesis. Previous reports have suggested 
that inflammatory stimuli could induce the expression of 
ICAM-117,22 and VCAM-122 in hiPSC-derived BMEC-like 
cells, but detailed characterization of the full panel of ad-
hesion molecules shown to mediate the multistep immune 
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cell migration across the BBB has not been reported. Here, 
we show that two different well-established protocols de-
veloped in our laboratory (co-differentiation unconditioned 
medium method (UMM)14,16,23 and chemically defined 
medium method (DMM)17) for differentiating hiPSCs to 
BMEC-like cell models yield BMEC-like cells lacking 
expression of several key adhesion molecules known to 
be involved in immune cell migration across the BBB in 
vivo. To address these specific shortcomings in current 
hiPSC-derived BBB models, we developed a new protocol 
to differentiate hiPSC-derived endothelial progenitor cells 
(EPCs) to BMEC-like cells that display an improved im-
mune phenotype, while also displaying barrier properties 
similar to those observed for primary human brain endo-
thelial cells.24–28 Overall, these cells faithfully reproduce 
the required molecular repertoire needed for the study of 
immune cell trafficking across the BBB.
2 |  MATERIALS AND METHODS
2.1 | Human induced pluripotent stem cells
Human induced pluripotent stem cells (hiPSCs) were re-
programmed, expanded, and characterized for pluripotency 
and differentiation capacity as described before.29 In brief, 
erythroblasts from three donors (age/sex: donor 1: 27/F, 
donor 2: 50/M, and donor 3: 49/F) were reprogrammed by 
nucleofection of plasmids encoding for OCT4, shRNA-
p53, SOX2, KLF4, L-Myc, and Lin28. Human iPSCs 
were cultured using ReproTeSR medium (STEMCELL 
Technologies) and expanded using StemMACS iPSC-
Brew XF medium (Miltenyi Biotec, Bergisch Gladbach). 
Five hiPSC clones from three donors (donor 1: 2 clones, 
donor 2: 2 clones, and donor 3: 1 clone) were used in this 
study. For some experiments, we also used the IMR90-4 
iPSC line.30 Human iPSCs were maintained on Matrigel 
(Corning)-coated plates in mTeSR1 medium (STEMCELL 
Technologies).
2.2 | Brain-like endothelial cells 
(BLECs) and primary BMECs
Brain-like endothelial cells (BLECs) were obtained exactly 
as described before.15,31 In brief, CD34+ cells were iso-
lated from human umbilical cord blood and differentiated 
to endothelial cells in ECM basal medium (ScienCell) sup-
plemented with 20% (v/v) fetal bovine serum (FBS; Life 
Technologies) and 50 ng/mL of VEGF165 (PeproTech Inc.). 
To induce a BBB phenotype, CD34+ cell-derived endothelial 
cells were cultured on Transwell filters (0.4  μm pore size, 
polycarbonate membrane, Corning 3401) and start co-culture 
with bovine pericytes at the same day for 6  days using 
ECM-5 medium (ECM basal medium (ScienCell) supple-
mented with 5% FBS, 1% endothelial cell growth supplement 
(ECGS; ScienCell), and 50  mg/mL gentamycin (Biochrom 
AG)). Primary human microvascular endothelial cells (pHB-
MECs) derived from autopsy tissue were purchased from 
PELOBiotech (Planegg/Martinsried). HBMECs were grown 
in endothelial cell medium supplemented with FBS, endothe-
lial cell growth supplement, and penicillin/streptomycin so-
lution (ScienCell Research Laboratories).
2.3 | Differentiation of hiPSCs into brain 
microvascular endothelial-like cells (BMEC-
like cells)
Unconditioned medium method (UMM)14,16 and defined me-
dium method (DMM)17 were slightly modified and used to 
differentiate BMEC-like cells. In brief, hiPSCs were seeded 
onto a Matrigel-coated plate in mTeSR1 supplemented with 
10 μmol/L ROCK inhibitor Y-27632 (Selleckchem, Houston, 
TX, USA) for 24 hours (day -3 or day -4). Seeding densities 
at day -3 or day -4 were optimized at 8,000/cm2 to 21,000/
cm2 for UMM, and between 35,000/cm2 to 150,000/cm2 
for DMM depending on donor and passage number (Table 
S1), in order to obtain transendothelial electrical resistance 
(TEER) of more than 2,000 Ω × cm2 and permeability to so-
dium fluorescein (NaFl, 376.3 Da) less than 0.6 × 10−4 cm/
min. hiPSCs were then expanded in mTeSR1 medium for 
2-3  days depending on hiPSC clone. At day 0, cells were 
induced to differentiate using specific medium for each 
method: For UMM, medium was switched to unconditioned 
medium (DMEM/F12 with 20% Knockout serum replace-
ment, 1× nonessential amino acids, 0.5× Glutamax, and 
0.1 mmol/L β-mercaptoethanol) and changed every day for 
6 days. For DMM, medium was switched to DeSR1 (DMEM/
F12 with 1× nonessential amino acids, 0.5× Glutamax, and 
0.1 mmol/L β-mercaptoethanol) supplemented with 6 μmol/L 
CHIR99021 (Selleckchem) and cultured for 24 hours. Then, 
the medium was switched to DeSR2 (DeSR1 plus 1× B27 
supplement) every day for another 5 days. At day 6, for both 
UMM and DMM, medium was switched to hECSR (human 
endothelial serum free medium (hESFM, Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with 1× B27 
and 20 ng/mL bFGF) and cultured for 2 days. For retinoic 
acid (RA) treatment, 10  μmol/L RA was added to hECSR 
medium. At day 8, cells were replated onto collagen IV 
(400  μg/mL)/fibronectin (100  μg/mL)- or Matrigel-coated, 
respectively, for UMM and DMM, Transwell filters (0.4 μm 
pore size, polycarbonate membrane, Corning 3401) or cul-
ture plates at 1,000,000/cm2 in hECSR medium. At day 9, the 
medium was switched to hECSR2 (hECSR lacking bFGF or 
RA) and cells were used for assays at day 10.
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2.4 | Differentiation of hiPSCs into 
endothelial progenitor cells (EPCs)
CD34+ CD31+ endothelial progenitor cells (EPCs) were dif-
ferentiated from hiPSCs as described.32,33 In brief, hiPSCs 
were seeded onto a Matrigel-coated plate in mTeSR1 supple-
mented with 5 μmol/L ROCK inhibitor Y-27632 for 24 hours 
(day -3). Seeding densities at day -3 were optimized between 
16,000/cm2 and 132, 000/cm2 depending on donor and pas-
sage in order to obtain high number of CD34+ CD31+ EPCs. 
At day 0 and day 1, medium was changed to LaSR basal 
medium (Advanced DMEM/F12, 2.5  mmol/L GlutaMAX, 
and 60  μg/mL ascorbic acid) supplemented with 8  μmol/L 
CHIR99021. At day 2, medium was switched to LaSR basal 
medium and changed every day for another 3 days. At day 5, 
CD31+ EPCs were purified using FITC-conjugated human 
CD31 antibody (Miltenyi Biotec, clone AC128) and EasySep 
Human FITC Positive Selection Kit II (STEMCELL 
Technologies) with an EasySep Magnet kit (STEMCELL 
Technologies). Purified EPCs were seeded onto collagen IV/
fibronectin-coated Transwell filters at a density of 100,000/
cm2 or collagen IV (10 μg/mL)-coated culture plates at a den-
sity of 10,000-20,000/cm2 in hECSR medium and used for 
assay or further extended EC culture.
2.5 | Extended endothelial cell culture 
method (EECM) and culture of smooth muscle-
like cells (SMLCs)
EPCs purified as described above were plated on colla-
gen IV (10 μg/mL)-coated plates in hECSR medium in the 
presence of 5 μmol/L ROCK inhibitor Y-27632 of 10,000-
20,000/cm2 as described before.33 Twenty-four hours later, 
medium was changed to hECSR without ROCK inhibitor 
and then, medium was changed every 2 days. Once the cells 
reached 100 % confluency (Figure 3B (a)), the cells were 
passaged using Accutase (Innovative Cell Technologies). 
In detail, medium was removed and 1  mL of Accutase 
was added to the 6-well plate and cells were carefully ob-
served under an inverted microscope (Zeiss Axiovert 25). 
Once endothelial cells started to become round (Figure 
3B (b)), the endothelial cells were physically detached by 
tapping the 6-well plate (Figure 3B (c)). Since endothelial 
cells detached earlier than non-endothelial cells, preferen-
tially detached endothelial cells were collected in a 15 mL 
conical tube containing 4 mL of hECSR and centrifuged, 
resuspended, and seeded onto collagen IV (400 μg/mL)/fi-
bronectin (100 μg/mL)-coated Transwell filters at a density 
of 100,000/cm2 or collagen IV (10 μg/mL)-coated culture 
plates at a density of 10,000-20,000/cm2 in hECSR me-
dium. These cell densities were found optimal for achieving 
closed monolayers. Coating with collagen IV/fibronectin 
for Transwell filters was chosen as it was previously shown 
to be optimal for growing primary BMECs and for UMM-
BMEC-like cells. Here, we found that the combination of 
collagen IV and fibronectin also enhanced adhesion of both 
EECM-BMEC-like cells and SMLCs. Therefore, we used 
only collagen IV (10 μg/mL)-coated culture plates during 
the selective passaging process to aid in SMLC depletion 
(Figure 3A). For clarity, we refer to D5 CD34+CD31+ cells 
as EPCs, and refer to cells that transitioned from EPCs to 
ECs after 6 days of culture in the EC culture medium as 
naïve ECs, and refer to “EECM-BMEC-like cells” starting 
at passage 2 (Figure 3A). In some experiments, EECM-
BMEC-like cells were cultured using ECM-5 medium. 
Human iPSC-derived SMLCs were obtained after harvest-
ing preferentially detached endothelial cells (Figure 3B 
(c)) by adding 2 mL of hECSR medium to 6-well plate and 
culturing ~6-10  days until confluence. Culture medium 
was collected every 2 days for SMLC-derived conditioned 
medium (CM). List of materials used in the EECM-BMEC-
like cell differentiation protocol is shown in Table S2.
2.6 | Co-culture of BMEC-like cells with 
pericytes, astrocytes, or SMLCs
Bovine pericytes,15 the human brain pericyte cell line 
(HBPCT),34 the human astrocyte cell line (hAST) 35, and 
hiPSC-derived astrocytes (iPS_AC)29 were obtained and 
maintained as previously described. Since HBPCT and hAST 
cell lines were immortalized with a temperature-depend-
ent SV40-antigen, these cells were expanded at 33°C and 
switched to 37°C when seeded for co-culture with EECM-
BEMC-like cells. HBPCT and hAST cells were shown before 
to stop proliferating 2  days after the temperature switch.36 
Generally, pericytes and astrocytes were seeded at a density 
of 26,000/cm2 for 2 days before starting the co-culture with 
EECM-BMEC-like cells using hECSR and incubated at 37°C 
(5% CO2) to become confluent. SMLCs were seeded at a den-
sity of 13, 000/cm2 1 day before starting the co-culture using 
hECSR. EECM-BMEC-like cells were seeded on collagen 
IV (400  μg/mL)/fibronectin (100  μg/mL)-coated Transwell 
inserts at a density of 100,000/cm2 and the co-culture was 
initiated on the same day. Co-cultures were maintained 
for 6  days using hECSR for both the apical and basolat-
eral compartment, with medium changes every other day. 
Transendothelial electrical resistance (TEER) was measured 
using a Volt-Ohm-Meter (Millicell ERS-2, MERSSTX01-
electrode). In order to calculate the net resistance in Ω × cm2 
of the cell monolayers, TEER value of an empty filter was 
subtracted from each measurement and TEER values in Ω 
were multiplied by the surface area of the filters (1.12 cm2) as 
follows: TEER (Ω × cm2) = (cell monolayer resistance (Ω) − 
empty Transwell filter resistance (Ω)) × surface area (cm2).
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2.7 | Treatment of EPCs with RA or 
pericyte conditioned medium (PCM)
EPCs purified as described above were plated on collagen 
IV (10 μg/mL)-coated plates in respective medium. For RA 
treatment, 10 μmol/L of RA was added to hECSR for 3 days 
and then, switched to hECSR medium without RA. For PCM 
treatment, bovine pericytes were cultured in hECSR medium 
at a density of 26,000/cm2 and culture medium was collected 
24 hours later and used as PCM. EPCs were treated with PCM 
for 6 days. After 6 days of culture, EPCs were detached with 
Accutase and seeded onto collagen IV/fibronectin-coated 
Transwell filters at a density of 100,000/cm2 in hECSR me-
dium. TEER values were measured over 6 days and perme-
ability assay was done at day 6 after seeding onto filters.
2.8 | Investigation of cell surface 
expression of adhesion molecules by 
flow cytometry
BMEC-like cells differentiated by UMM, DMM, or EECM 
and naïve ECs were cultured on collagen IV (10  μg/mL)-
coated plates at a density of 10,000/cm2 or collagen IV 
(400 μg/mL)/fibronectin (100 μg/mL)-coated Transwell in-
serts at a density of 100,000/cm2 in respective media. Some 
wells were stimulated with 10 ng/mL of recombinant human 
TNF-α (R&D Systems, 210TA) and 200 IU/mL recombinant 
human IFN-γ (R&D systems, 285IF) for UMM- or DMM-
differentiated BMEC-like cells, and 1 ng/mL of recombinant 
human TNF-α and 20  IU/mL recombinant human IFN-γ, 
or 1  ng/mL of recombinant human IL-1β (R&D systems, 
201-LB/CF) for EECM-BMEC-like cells or naïve ECs for 
16 hours at 37°C (5% CO2). Stimulated and non-stimulated 
control cells were gently detached with Accutase, washed, 
and resuspended in FACS-buffer (DPBS (1×), 2.5% FBS, 
0.1% NaN3). Then, 1 × 10
5 cells per well were transferred 
to a 96-well microtiter plate and incubated 20 minutes on ice 
with the fluorochrome-conjugated antibodies or respective 
isotype controls (Table S3). After staining, cells were washed 
twice with DPBS and measured with an Attune NxT Flow 
Cytometer (Thermo Fisher Scientific). Data were analyzed 
using FlowJo 10 software (Tree Star).
2.9 | Western blotting
Naïve ECs (passage 1) and EECM-BMEC-like cells (pas-
sages 2 and 3) were lysed with RIPA buffer supplemented 
with Halt protease inhibitor cocktail (Thermo Scientific, 
78430). The BCA assay (Pierce BCA Protein Assay Kit: 
Thermo Scientific, 23227) was used to determine the pro-
tein concentration and 23 μg of protein resolved on 4%-12% 
tris-glycine gels. Proteins were transferred to nitrocellulose 
membranes and blocked for 1  hour at room temperature 
in tris-buffered saline supplemented with 0.1% Tween 20 
(TBST) and 5% nonfat dry milk. Membranes were incubated 
with primary antibodies (Table S4) diluted in TBST + 5% 
nonfat dry milk overnight at 4°C. Membranes were washed 
5× with TBST and incubated with infrared-labeled secondary 
antibodies (Table S4) diluted in TBST + 5% nonfat dry milk 
for 1  hour at room temperature. Membranes were washed 
5× with TBST and imaged using a LI-COR Odyssey Classic 
(9120). Quantification of band intensity was performed using 
LI-COR Image Studio software.
2.10 | Immunofluorescence staining
BMEC-like cells differentiated by UMM, DMM, or EECM, 
naïve ECs, and SMLCs were cultured on Transwell in-
serts as described above or collagen IV (10 μg/mL)-coated 
chamber slides (Thermo Fisher Scientific). Same amounts 
of pro-inflammatory cytokine (1  ng/mL TNF-α + 20  IU/
mL IFN-γ or 1  ng/mL IL-1β) for Transwell inserts dis-
rupted the EECM-BMEC-like cell monolayers grown on 
chamber slides; therefore, we titrated and used 0.1 ng/mL 
TNF-α + 2  IU/mL IFN-γ or 0.1 ng/ml IL1-β for stimula-
tion of EECM-BMEC-like cells cultured on chamber slides. 
To stain for claudin-5, occludin, VE-cadherin, PECAM-1, 
ZO-1, and N-cadherin cells were fixed with −20°C pre-
cooled methanol for 20  seconds and rehydrated during 
subsequent washing steps in PBS. Cells were blocked and 
permeabilized with 5% skimmed milk containing 0.1% 
Triton X-100 for 10 minutes at RT, and then, stained with 
primary antibodies diluted in 5% skimmed milk in PBS for 
1 hour at RT as described.16,17,37 For staining of the adhe-
sion molecules ICAM-1, ICAM-2, VCAM-1, ALCAM, 
and MCAM, primary antibodies were diluted in hECSR 
medium and added to live cells and incubated at 37°C (5% 
CO2) for 15 minutes. This allowed for selective detection of 
cell surface-expressed adhesion molecules, which are func-
tionally available for immune cell interaction. After wash-
ing with PBS, cells were fixed with 1% (w/v) formaldehyde 
in PBS for 10 minutes at RT. Cells were washed with PBS 
and blocked with 5% skimmed milk in PBS for 10 minutes 
at RT and then, incubated with secondary antibodies for 
1 hour at RT as described.37 For the staining of P-selectin, 
E-selectin, CD99, ⍺-smooth muscle actin, NG2, and vi-
mentin, cells were first fixed with 1% (w/v) formaldehyde 
in PBS for 10  minutes at RT and blocked and permeabi-
lized with 5% skimmed milk in PBS containing 0.1% Triton 
X-100 for 10 minutes at RT. Cells were then incubated with 
primary antibodies for 1 hour at RT diluted in 5% skimmed 
milk in PBS. To stain for calponin and SM22⍺, cells were 
fixed with 4% (w/v) formaldehyde in PBS, blocked and 
16698 |   NISHIHARA et Al.
permeabilized with 3% BSA in PBS containing 0.1% Triton 
X-100 for 1 hour at RT, and then, stained with primary anti-
bodies at 4°C overnight as described.38 After three washes, 
cells were incubated with respective secondary antibodies 
for 1 hour at RT. Nuclei were stained with DAPI at 1 µg/mL 
or Hoechst 33342 at 4 µmol/L. After washing with DPBS, 
cell monolayers on filters or chamber slides were mounted 
with Mowiol (Sigma-Aldrich). Images were acquired using 
a Nikon Eclipse E600 microscope or Nikon Eclipse Ti2-E 
microscope using the Nikon NIS-Elements BR3.10 software 
(Nikon) or inverted research microscope Axio observer Z1 
(63x immersion oil, Apotome mode, Zeiss) equipped with 
a camera (Zeiss Axiocam MRm) and the ZEN-blue soft-
ware. List of antibodies used in this study is shown in Table 
S5. Quantification of EC shape was performed using VE-
cadherin immunofluorescence images by an observer blind 
to the experimental groups. For each image, FIJI (ImageJ) 
software was used to trace ten cell outlines, and the Shape 
Descriptors tool under the Set Measurements function of 
FIJI was used to calculate circularity values (4 × π × area/
perimeter2); average cell circularity for each image is 
reported.
2.11 | Permeability (Pe) assay
Permeability of EC monolayers was assessed by measuring 
the clearance of sodium fluorescein (NaFl, 376.3 Da, Sigma-
Aldrich) as previously described.16 Briefly, NaFl was added 
to the upper compartment of the Transwell inserts at a con-
centration of 10 μmol/L. Medium samples containing fluo-
rescent tracer that had diffused across the monolayers were 
collected from the bottom well every 15 minutes for a total 
of 60 minutes, and fluorescence intensity was measured in a 
Tecan Infinite M1000 multi-well reader (Tecan Trading AG). 
The clearance principle was used to calculate the permeabil-
ity coefficient (Pe) and to obtain a concentration-independent 
transport parameter as previously described in detail.16 This 
method includes blank filters without cells as a control to 
measure clearance across the filter membrane for appropriate 
calculation of the Pe across the endothelium (Pe). The experi-
ments were done in triplicates for each condition.
2.12 | Human Th1* cells
Human CD4+ T cells were isolated and sorted as previ-
ously described.39,40 In brief, human Th1* cells were iso-
lated by fluorescence-activated cell sorting according to 
their specific expression pattern of chemokine receptors 
(CXCR3+CCR4−CCR6+) from the peripheral blood of healthy 
donors. T cells were expanded for 20 days with periodic re-
stimulation with 1  μg/mL phytohemagglutinin, irradiated 
allogeneic peripheral blood mononuclear cells, and human 
interleukin 2 (IL-2, 500 IU/mL) as previously described.39,40 
After 20 days of expansion, T cells were frozen and stored in 
liquid nitrogen until employed in the experiments. T cells were 
thawed 1 day prior to the respective experiment and labeled 
with 1 μmol/L CellTracker Green (CMFDA Dye, Life tech-
nologies) at 37°C (5% CO2) for 30 minutes on the day of the 
experiment. After labeling, T cells were washed and dead cells 
were removed by Ficoll-Hypaque gradient (780g, 20 minutes, 
20°C). T cells were washed twice and resuspended in migra-
tion assay medium (DMEM supplemented with 5% FBS, 
4 mmol/L L-Glutamine and 25 mmol/L HEPES) at concentra-
tions as described below.
2.13 | Adhesion assay under static condition
EECM-BMEC-like cells were cultured on collagen IV 
(10  μg/mL)-coated 16-well chamber slides (Thermo 
Fisher Scientific) at a density of 100,000/cm2 in hECSR 
medium or CM derived from SMLCs. EECM-BMEC-like 
cells were stimulated with 0.1 ng/mL recombinant human 
IL-1β or 0.1 ng/mL TNF-α + 2 IU/mL IFN-γ for 16 hours 
at 37°C (5% CO2), or maintained as non-stimulated con-
trols. EECM-BMEC-like cell monolayers were washed 
twice with migration assay medium and 20,000 Th1* cells 
were added on top of EECM-BMEC-like cell monolayers 
and incubated at RT for 30 minutes using a rocking plat-
form. Chamber slides were gently washed twice and fixed 
with 2.5% glutaraldehyde for 2  hours on ice. Chamber 
slides were then washed with DPBS and adherent fluores-
cencently labeled Th1* cells per pre-defined field of view 
(FOV) were analyzed by fluorescence microscopy (Nikon 
Eclipse E600) and FIJI software (Version 2.0.0, Image J). 
The average number of adherent cells/FOV was determined 
counting two fields per well. Assays were performed in at 
least triplicates for each condition.
2.14 | T-cell arrest to EECM-BMEC-like 
cells under flow
EECM-BMEC-like cells were seeded in cloning rings placed 
on collagen IV (10  μg/mL)-coated Ibidi μ-dishes (Ibidi) at 
a density of 100,000/cm2. EECM-BMEC-like cells were 
stimulated with 0.1  ng/mL recombinant human IL-1β for 
16 hours at 37°C (5% CO2). Live cell imaging was done as 
described.41 In brief, Th1* cells were perfused over EECM-
BMEC-like cell monolayers and allowed to accumulate for 
4 minutes using low shear stress (0.1 dynes/cm2). Thereafter, 
flow was increased to physiological shear stress (1.5 dynes/
cm2). Thirty seconds after increasing shear stress, the number 
of arrested Th1* cells was counted.
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2.15 | In vitro live cell imaging
EECM-BMEC-like cells were cultured in cloning rings 
placed on collagen IV (10  μg/mL)-coated Ibidi μ-dishes 
(Ibidi) at a density of 75,000/cm2. EECM-BMEC-like cells 
were stimulated with 0.1 ng/mL recombinant human TNF-α 
+ 2 IU/mL IFN-γ for 16 hours at 37°C (5% CO2) diluted in 
CM from SMLC. Fluorescencently labeled Th1* cells were 
allowed to accumulate on the EECM-BMEC-like cell mon-
olayer at a low flow rate of 0.1 dynes/cm2 for 4 minutes from 
the first frame after the first Th1* cells appeared in the FOV 
(accumulation phase until 3 minutes 55 seconds). After the 
accumulation phase of precisely 3 minutes 55 seconds, the 
flow rate was set to the physiological level of 1.5 dynes/cm2 
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for 16 minutes (shear phase). The dynamic T-cell interactions 
with the EECM-BMEC-like cell monolayers under the physi-
ological flow were recorded at a 10x magnification with a 
Zeiss Axiocam MRm camera. During the recording, 1 image 
was acquired every 5 seconds, then the video was exported 
with a frame rate of 30 images/second. T-cell behavior on the 
EECM-BMEC-like cell monolayer was categorized as de-
scribed previously.37 In brief, T cells found to polarize upon 
arrest and to migrate across the EECM-BMEC-like cells 
monolayer with or without prior crawling or probing on the 
EECM-BMEC-like cells were categorized as “diapedesis.” 
T cells that crawled on the surface of the EECM-BMEC-
like cells for the entire observation time were categorized 
as “crawling.” T cells that remained stationary without dis-
placing beyond a distance exceeding their own diameter and 
presenting dynamic cellular protrusions were categorized as 
“probing.”
2.16 | Statistical analysis
Statistical analyses comprising calculation of degrees 
of freedom were done using GraphPad Prism 7 software 
(Graphpad software, La Jolla, CA, USA). Data are shown 
as the mean ± SD. To compare two groups, statistical sig-
nificance was assessed by paired or unpaired t test, while 
more groups were analyzed by one-way ANOVA followed 
by Tukey’s multiple comparison test (*P < .05, **P < .01, 
***P  <  .001, ****P  <  .0001). The respective statistical 
methodology used for each assay is specified in corre-
sponding figure legends.
3 |  RESULTS
3.1 | BMEC-like cells differentiated by 
UMM or DMM are not suitable for studying 
immune cell interactions
We first explored if BMEC-like cells differentiated by the 
UMM or DMM express and display cytokine-induced up-
regulation of adhesion molecules described for the BBB in 
vivo.4 To this end, we performed flow cytometry analysis 
of non-stimulated (NS) or pro-inflammatory cytokine-stim-
ulated (10 ng/mL TNF-α + 200 IU/mL IFN-γ) BMEC-like 
cells differentiated by UMM or DMM for the BBB adhe-
sion molecules ICAM-1, ICAM-2, VCAM-1, P-selectin, 
E-selectin, and the junctional molecules CD99 and PECAM-
1. UMM- and DMM-differentiated BMEC-like cells ex-
pressed CD99, PECAM-1, and ICAM-1, the latter only being 
further increased after stimulation with pro-inflammatory 
cytokines (Figure 1A,B,E). At the same time, UMM- and 
DMM-differentiated BMEC-like cells did not stain posi-
tive for ICAM-2, VCAM-1, E-selectin, or P-selectin. Since 
RA has been reported to inhibit upregulation of endothelial 
VCAM-1 in vitro,42 we asked if omitting RA treatment influ-
ences the adhesion molecule profile of UMM- and DMM-
differentiated BMEC-like cells. Completely omitting RA 
treatment during the whole differentiation process allowed 
for enhanced cytokine-induced upregulation of ICAM-1 on 
UMM- or DMM-differentiated BMEC-like cells, but did not 
affect lack of detection of P-selectin, E-selectin, ICAM-2, 
and VCAM-1 (Figure 1C-E; Figure S1). UMM- and DMM-
differentiated BMEC-like cells thus lack expression of the 
full array of vascular cell adhesion molecules necessary to 
support the sequential multistep immune cell adhesion cas-
cade characterized by rolling, arrest, polarization, crawling 
of the immune cell on, and diapedesis across the BBB under 
physiological flow. Thus, the well-established methods for 
differentiating hiPSC-derived BMEC-like cells are not well 
suited for modeling immune cell interactions at the BBB in 
the configurations studied here.
3.2 | hiPSC-derived ECs display a BBB 
immune phenotype but lack barrier properties
We have previously shown that human CD34+ cord blood 
stem cells can be differentiated into CD34+ EPCs and finally 
by co-culture with pericytes into BLECs that display endothe-
lial adhesion molecule expression similar to that observed in 
vivo.15,31 Therefore, we first asked if hiPSC-derived naïve 
ECs could exhibit a mature immune phenotype with respect 
to expression of endothelial adhesion molecules. To this end, 
F I G U R E  1  Adhesion molecule phenotype of BMEC-like cells differentiated by the unconditioned medium method (UMM) or the defined 
medium method (DMM). Cell surface staining of BMEC-like cells differentiated by UMM (A, C) or DMM (B, D) in the presence or absence of RA 
for the adhesion molecules ICAM-1, ICAM-2, VCAM-1, P-selectin, E-selectin, CD99, and PECAM-1 was analyzed by flow cytometry. Isotype 
control, non-stimulated (NS), and 16 h pro-inflammatory cytokine-stimulated condition (10 ng/mL TNF-α + 200 IU/mL IFN-γ) are represented in 
gray, blue, and red, respectively, in a histogram overlay. Representative data from donor 2 are shown. At least three independent differentiations 
were performed in each condition using two different hiPSC clones derived from two different donors (donor 2 and 3) for UMM-differentiated 
BMEC-like cells and three hiPSC clones from three donors (donor 1, 2, and 3) for DMM-differentiated BMEC-like cells with comparable data 
observed (eg, Figure S1). E, The Δ geometric mean (MFI staining–MFI isotype) of cell surface adhesion molecules of UMM- or DMM-BMEC-like 
cells were analyzed by flow cytometry. Displayed are the mean ∆MFI for each donor (donor 1: black, donor 2: red, and donor 3: blue). Mean ± 
S.D. from triplicate differentiations were used in a paired students t test to determine statistically significant changes upon stimulation (*P < .05, 
**P < .01).
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we generated CD34+CD31+ EPCs from hiPSCs using an es-
tablished protocol (Figure 3A)32,33 and transitioned them to 
naïve ECs by 6  days of culture in the EC culture medium 
(hECSR medium: human endothelial serum-free medium + 
1× B-27 supplement + 20  ng/mL bFGF) and investigated 
the cell surface expression of adhesion molecules. Under 
NS conditions, hiPSC-derived ECs expressed ICAM-1, 
ICAM-2, E-selectin, CD99, and PECAM-1, while under pro-
inflammatory cytokine (1 ng/mL TNF-α + 20 IU/mL IFN-γ)-
stimulated conditions, ICAM-1 was upregulated, as expected 
(Figure 2A,B, Figure S2A). In addition, we found that 
hiPSC-derived ECs expressed VCAM-1 and P-selectin upon 
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pro-inflammatory cytokine stimulation (Figure 2A,B, Figure 
S2A). Thus, these naïve ECs may be suitable for modeling 
aspects of the BBB immune phenotype. However, since these 
ECs were not specified to a BMEC-like fate, barrier charac-
teristics of hiPSC-derived naïve ECs as measured by TEER 
and permeability to the small molecule tracer sodium fluores-
cein with an average molecular weight of 0.37 kDa (PeNaFl), 
were minimal. We failed to detect a measurable TEER across 
the naïve EC monolayer and detected a high permeability to 
sodium fluorescein (Figure 3F, P1; PeNaFl: 2-10 × 10
−3 cm/
min). Thus, while hiPSC-derived ECs exhibit improved ad-
hesion molecule expression compared to UMM- and DMM-
differentiated BMEC-like cells, they fail to establish barrier 
properties characteristic of the BBB.
3.3 | Extended passaging drives naïve 
hiPSC-derived ECs to BMEC-like cells
Since studying immune cell interactions at the BBB requires 
both adhesion molecule phenotypes and tight junction pheno-
types critical to the process of T-cell diapedesis, we next aimed 
to identify strategies to drive the development of barrier proper-
ties in hiPSC-derived EC monolayers. When EPCs were tran-
sitioned to ECs, a mixed population of ZO-1+/VE-cadherin+ 
ECs and VE-cadherinneg cells resulted (Figure 2C). Thus, de-
spite the presence of junction-associated ZO-1- and adherens 
junction-associated VE-cadherin-expressing cells, even a min-
imal barrier could not be detected as a complete EC monolayer 
could not form. Since EPCs have been reported to have the 
capacity to differentiate to both ECs and smooth muscle cells, 
depending on the medium used for differentiation,32 PECAM-
1neg cells were tested to determine if they expressed ⍺-smooth 
muscle actin (⍺-SMA). Indeed, the majority of PECAM-1neg 
cells stained positive for ⍺-SMA (Figure S2B,C), underscor-
ing that a fraction of the EPCs differentiated to SMLCs despite 
being cultured in EC-inductive medium.
We, therefore, aimed to generate pure naïve EC monolay-
ers in order to test the hypothesis that reducing SMLC con-
tamination in the EC monolayers would improve their basal 
barrier properties. Careful microscopic observation of the 
EC cultures during the detachment process when performing 
standard culture passaging showed that ECs detached earlier 
compared to non-ECs (Figure 3B). Selective passaging of the 
preferentially detached ECs yielded EC monolayers with en-
riched purity that by passage 2, developed elevated TEER (at 
day 6 after passaging: 62.4 ± 9.0 Ω × cm2) and ~10-fold lower 
permeability (PeNaFl = (0.279 ± 0.124) × 10
-3 cm/min) when 
compared to naïve ECs (Figure 3E,F). These ECs formed by 
the EECM, also maintain barrier characteristics over several 
passages. EECM-differentiated ECs showed increased purity 
of VE-cadherin+ cells (Figure S2D) and stable barrier charac-
teristics with TEER above 60 Ω × cm2 and low permeability 
to sodium fluorescein (PeNaFl < (0.32 ± 0.1) × 10
−3 cm/min) 
until at least passage 5 (Figure 3E,F). The barrier properties 
of EECM-differentiated ECs are comparable to or even tighter 
than those measured in primary human brain microvascular 
endothelial cells,13,28 and similar to those observed in BLECs 
differentiated from primary CD34+ progenitors.15 Correlating 
with the enhanced barrier properties upon passage, the passage 
2-4 EECM-differentiated ECs exhibited increased expression 
of claudin-5 and improved junctional localization of both oc-
cludin and claudin-5 when compared to passage 1 naïve ECs 
(Figure 3C). Western blotting confirmed expression of adher-
ens and tight junction-associated proteins (VE-cadherin, oc-
cludin, claudin-5, ZO-1), Von Willebrand factor (vWF), and 
caveolin-1, with claudin-5 abundance increasing after extended 
passage culture (Figure S3A,B). Thus, improved barrier prop-
erties as measured by TEER and PeNaFl are likely a result of im-
proved EC purity and improved expression and localization of 
important BBB tight junction proteins occludin and claudin-5. 
We further confirmed that the EECM differentiation protocol 
works independently of hiPSC origin using the fibroblast-re-
programmed IMR90-4 line (Figure S3C-E). In addition, im-
munofluorescence staining of passage 5 ECs showed that these 
ECs develop a flat morphology with flat nuclei which overall 
resembles the typical morphology of brain endothelial cells 
(Figure 3C,D, Figure S1C). Since EECM-differentiated ECs 
formed a diffusion barrier as marked by a low PeNaFl value, 
and showed cellular and junctional morphology reminiscent of 
that observed for BBB endothelium in vivo, we term the cells 
generated by this new protocol EECM-BMEC-like cells.
F I G U R E  2  Adhesion molecule phenotype and morphology of hiPSC-derived naïve ECs. A, Cell surface staining of hiPSC-derived naïve ECs 
for the adhesion molecules ICAM-1, ICAM-2, VCAM-1, P-selectin, E-selectin, CD99, and PECAM-1 was analyzed by flow cytometry. Isotype 
control, non-stimulated (NS), and 16 h pro-inflammatory cytokine-stimulated condition (1 ng/mL TNF-α + 20 IU/mL IFN-γ) are represented in 
gray, blue, and red, respectively, in a histogram overlay. Representative data from donor 2 are shown. Three independent differentiations were 
performed using three hiPSC clones from three donors (donor 1, 2, and 3) showing comparable data (eg, Figure S2). B, The Δ geometric mean 
(MFI staining–MFI isotype) of cell surface adhesion molecules of naïve ECs were analyzed by flow cytometry. Displayed are the mean ∆MFI for 
each donor (donor 1: black, donor 2: red, and donor 3: blue). Mean ± S.D. from triplicate differentiations were used in a paired students t test to 
determine statistically significant changes upon stimulation (*P < .05). C, Immunofluorescence staining of hiPSC-derived naïve ECs grown on 
0.4 µm pore Transwell filter inserts for ZO-1 (red) or VE-cadherin (red), and nuclei (DAPI, blue) is shown. Arrow depicts VE-cadherin negative 
cells. Representative data from donor 2 are shown. Each staining is representative of at least three independent differentiations. Three hiPSC clones 
from three donors (donor 1, 2, and 3) were used in this assay and at least three independent differentiations were performed in each donor. Scale 
bars = 100 μm.
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3.4 | Astrocytes and pericytes affect 
morphology but not diffusion barrier 
characteristics of EECM-BMEC-like cells
Barrier properties of brain endothelial cells are not intrin-
sic and rather rely on developmental cues and continuous 
cross-talk with cells from the neurovascular unit such as peri-
cytes and astrocytes. Indeed, previous observations from us 
and others have shown that astrocyte or pericyte co-culture 
can induce barrier characteristics in BLECs and hiPSC-
derived BMEC-like cells.15,38,43 To determine if barrier 
properties of EECM-BMEC-like cells (passages 3-5) could 
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be improved by co-culture with astrocytes or pericytes, we 
grew EECM-BMEC-like cells (passages 3-5) on Transwell 
filters and co-cultured them for 6 days with bovine pericytes 
(bovine-PC15), a human brain pericyte cell line (HBPCT34), 
a human astrocyte cell line (hAST35), or hiPSC-derived as-
trocytes (iPSC_AC29) in the lower chamber (Figure 4A). 
We also tested RA treatment for the first 2 days of passage 
3 since RA has been reported to improve barrier properties 
of hiPSC-derived BMEC-like cells.23 Barrier characteristics 
of monocultured EECM-BMEC-like cells were not enhanced 
by co-culture or RA treatment as indicated by indistinguish-
able TEER and NaFl permeability measurements (Figure 
4B,C; Figure S4A-F). Immunofluorescent detection of VE-
cadherin, claudin-5, and occludin did not reveal any obvious 
differences in staining levels or junctional localization upon 
co-culture with hiPSC-derived astrocytes or the HBPCT. 
However, EECM-BMEC-like cells exhibited a higher den-
sity cell monolayer and a more elongated morphology com-
pared to the monoculture condition (Figure 4D-F). Thus, 
EECM-BMEC-like cells respond to factors secreted by as-
trocytes and pericytes, but these factors did not enhance dif-
fusion barrier properties.
To understand the relevance of culture medium compo-
sition on barrier properties of EECM-BMEC-like cells, we 
also employed ECM-5 medium, which we have previously 
used in the human CD34+ cord blood stem cell-derived 
BLECs model.15 Culturing EECM-BMEC-like cells (pas-
sage 3-5) in the presence of bovine pericytes in ECM-5 me-
dium improved barrier properties as shown by the significant 
reduction of their permeability to NaFl when compared to 
monoculture conditions (Figure S4G). However, irrespec-
tive of monoculture or co-culture, PeNaFl was extremely 
high when compared to EECM-BMEC-like cells cultured 
in hECSR medium (Figure S4G vs Figure S4C; ECM-5 
monoculture 2.875 ± 0.641 × 10−3 cm/min, ECM-5 bovine 
pericyte co-culture 1.180  ±  0.424  ×  10−3  cm/min, hECSR 
monoculture 0.221 ± 0.064 × 10−3 cm/min, hECSR bovine 
pericyte co-culture 0.223  ±  0.058  ×  10−3  cm/min). Thus, 
hESCR medium plays an important role in driving barrier 
formation in EECM-BMEC-like cells.
We next tested if differentiating cells in the potentially 
more plastic, early stages of EPC-to-EC transition (ie, first 
several days of culture after EPC purification by MACS, 
Figure 3A) were more responsive to RA treatment or secreted 
factors present in PCM. After EPC purification, EPCs were 
cultured with either RA for 3 days or PCM for 6 days and 
then, upon reaching passage 2, the resulting ECs were seeded 
onto Transwell filters. Comparing the TEER and permeabil-
ity for NaFl, we found that neither RA nor PCM pre-treatment 
improved barrier properties. Instead, PCM pre-treatment in-
creased the PeNaFl of the EECM-BMEC-like cell monolayer 
(Figure S4H,I). Given the minimal impact of co-cultured as-
trocytes, pericytes and RA treatment on the barrier properties 
in EECM-BMEC-like cells, these conditions were not further 
investigated.
3.5 | Adhesion molecule phenotype of 
EECM-BMEC-like cells
We next asked if the extended passaging of naïve ECs to 
EECM-BMEC-like cells impacted the adhesion molecule 
repertoire observed for naïve ECs in Figure 2. Much like naïve 
ECs, EECM-BMEC-like cells expressed cell surface ICAM-
1, ICAM-2, CD99, PECAM-1, E-selectin, and P-selectin 
under NS conditions (Figure 5A-C; Figure S5A,B). Pro-
inflammatory cytokine (1 ng/mL TNF-α + 20 IU/mL IFN-γ) 
stimulation-induced upregulated expression of ICAM-1 and 
F I G U R E  3  Extended endothelial cell culture method (EECM). A, Schematic representation of the protocols used for extended endothelial 
cell culture method (EECM). B, Phase contrast images of hiPSC-derived naïve ECs before (i) and after (ii) incubation with Accutase, and 
after detachment of ECs by tapping the plate (iii). Red arrow shows non-ECs remaining attached to the plate. Scale bars = 100 μm. C, 
Immunofluorescence staining of naïve ECs (passage 1) or EECM-BMEC-like cells (passages 2-4) grown on chamber slides. Junctions were 
stained for VE-cadherin (red), PECAM-1 (red), ZO-1 (green), claudin-5 (red), or occludin (red), and nuclei were stained with DAPI (blue). Scale 
bars = 50 μm. D, Immunofluorescence images of EECM-BMEC-like cells (passage 5) grown on 0.4 µm pore Transwell filters. Cell junctions 
were stained for VE-cadherin (red) or zonula occludens 1 (ZO-1, red), and nuclei were stained with DAPI (blue). Each panel shows a xy en face 
view of a maximum-intensity projection through the z-axis. The top (xz) and right (yz) side panels indicate the flat morphology of the EECM-
BMEC-like cells with staining for cell nuclei and ZO-1 at the same level in the z-axis. Scale bars = 20 µm. (C, D) Representative images from 
donor 2 are shown. Five hiPSCs clones from three donors (donor 1, 2, and 3) were used in this assay and at least three independent differentiations 
were performed for each clone producing comparable results. E, Time-dependent progression of transendothelial electrical resistance (TEER) of 
EECM-BMEC-like cell monolayers derived from donor 2. EECM-BMEC-like cells (passage 2: red, passage 3: green, passage 4: blue, passage 5: 
orange) were grown to confluency on 0.4 μm pore size Transwell filters for 6 days. Passage 1 naïve ECs show no measurable TEER. Plotted data 
are mean TEER values ± SD. Data are combined from at least three independent differentiations for each passage, each measurement performed 
in triplicates. F, Permeability of 0.37 kDa sodium fluorescein (NaFl): naïve ECs (passage 1: black) or EECM-BMEC-like cells (passage 2: red, 
passage 3: green, passage 4: blue, passage 5: orange) derived from donor 2 were cultured to confluency on 0.4 μm pore size Transwell filters for 
6 days and permeability was measured at day 6. Bars show the mean permeability coefficients (Pe) ± SD. Data are combined from at least three 
independent differentiations each performed in triplicate per condition. Statistical analysis: one-way ANOVA followed by Tukey’s multiple 
comparison test. (****P < .0001).
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P-selectin, but did not change the levels of ICAM-2 and CD99 
(Figure 5A, B). With this adhesion molecule phenotype, 
EECM-BMEC-like cells differ substantially from UMM- or 
DMM-differentiated BMEC-like cells and resemble brain 
like endothelial cells (BLECs15) and primary human brain 
endothelial cells previously shown to express BBB adhesion 
molecules44 (Figure S6). We also confirmed ALCAM and 
MCAM expression by EECM-BMEC-like cells using im-
munostaining (Figure S5C). In contrast to the findings with 
naïve ECs, we found only subtle upregulation of VCAM-1 
on TNF-α/ IFN-γ-stimulated EECM-BMEC-like cells 
(Figure 5A-C and Figure S5A) or 1 ng/mL IL-1β-stimulated 
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EECM-BMEC-like cells (Figure S5B). TNF-α/ IFN-γ- or 
IL-1β-stimulated EECM-BMEC-like cells showed similar 
levels of cell surface ICAM-1 and VCAM-1 (Figure S5D). 
Moreover, increasing the concentration of pro-inflammatory 
cytokines or using different combinations thereof resulted 
in disruption of EECM-BMEC-like cell monolayers (Figure 
S5E) rather than increasing the endothelial surface staining 
for ICAM-1 and VCAM-1.
3.6 | EECM-BMEC-like cells express 
VCAM-1 and functional ICAM-1
Since EECM-BMEC-like cells possess both barrier and im-
mune phenotypes that would potentially be valuable for inves-
tigating immune cell interactions with the BBB, we wished 
to determine the functional relevance of endothelial ICAM-1 
and VCAM-1 on EECM-BMEC-like cells. To this end, we 
investigated the adhesion of Th1* cells on NS and TNF-α/ 
IFN-γ-stimulated and IL-1β-stimulated EECM-BMEC-like 
cells (passages 3-5) under static conditions. Cytokine stim-
ulation significantly increased the numbers of Th1* cells 
adhering to EECM-BMEC-like cell monolayers (Figure 
5D). Antibody-mediated blocking of endothelial ICAM-1 
and its respective β2-integrin ligand on Th1* cells signifi-
cantly reduced adhesion of Th1* cells to cytokine stimulated 
EECM-BMEC-like cells (Figure 5E). Antibody-mediated 
blocking of α4β1-integrins on Th1* cells also reduced adhe-
sion of Th1* cells to cytokine stimulated EECM-BMEC-like 
cells, but blocking of the endothelial α4β1-integrin ligand 
VCAM-1 did not significantly reduce Th1* adhesion (Figure 
5E). α4β1-integrin-mediated arrest of Th1* cells was also 
confirmed on cytokine-stimulated EECM-BMEC-like cells 
under physiological flow (Figure 5F). Taken together, these 
data demonstrate that EECM-BMEC-like cells express func-
tional ICAM-1 supporting β2-integrin-dependent adhesion 
of Th1* cells. Furthermore, EECM-BMEC-like cells also 
support α4β1-integrin-mediated arrest of Th1* cells, where 
VCAM-1 does not visibly contribute to this process.
3.7 | Smooth muscle-like cells (SMLCs) 
induce robust functional VCAM-1 expression 
on EECM-BMEC-like cells
As the α4-integrin/VCAM-1 interaction, in addition to 
LFA-1/ICAM-1, has been reported to mediate CNS entry of 
T and B cells in CNS autoimmunity,6,45 we explored further 
strategies to enhance expression of VCAM-1 on EECM-
BMEC-like cells. In peripheral endothelial cell cultures, 
co-culture with smooth muscle cells was shown to enhance 
endothelial VCAM-1 expression.46 Therefore, we asked 
if hiPSC-derived SMLCs could increase the expression of 
VCAM-1 in EECM-BMEC-like cells. Human iPSC-derived 
SMLCs were obtained by continued culture of adherent cells 
after selective detachment of endothelial cells for derivation 
of EECM-BMEC-like cells (Figure 3A,B). These SMLCs 
expressed proteins characteristic of smooth muscle cells, in-
cluding ⍺-SMA, calponin, and smooth muscle protein-22⍺ 
(Figure S7). Next, the SMLCs were co-cultured with EECM-
BMEC-like cells (passage 3-5) on Transwell filters for 6 days 
and VCAM-1 staining on EECM-BMEC-like cells was com-
pared before and after cytokine stimulation. We found that 
co-culture of EECM-BMEC-like cells with SMLCs signifi-
cantly increased cell surface expression of VCAM-1 after 
TNF-α/ IFN-γ-stimulation, while there was no overt change 
to cell surface levels of ICAM-1, ICAM-2, PECAM-1, 
CD99, E-selectin, or P-selectin under either NS or stimulated 
F I G U R E  4  Effect of co-culture with astrocytes or pericytes on EECM-BMEC-like cell monolayers. A, Schematic representation of the 
protocols for EECM-BMEC-like cells co-cultured with astrocytes or pericytes, or RA treatment is shown. B, TEER and (C) permeability of sodium 
fluorescein of EECM-BMEC-like cell monolayers are shown. EECM-BMEC-like cells (from passages 3-5) were seeded onto 0.4 μm pore size 
Transwell filters and co-cultured for 6 days with bovine pericytes ((bovine PC): light green), a human brain pericyte cell line ((HBPCT): green), 
a human astrocyte cell line ((hAST): dark red), hiPSC-derived astrocytes ((iPS_AC): pink), or treated with RA for 2 days (purple). Monoculture 
was used as a control (black). B, Plotted data are mean TEER values ± SD. C, Bars show the mean permeability coefficients (Pe) ± SD. (B, C) 
Data are from at least three independent differentiations for co-cultures each performed in triplicate using the same hiPSC clone. Representative 
data from donor 2 are shown. The following clones were tested for each condition: three hiPSC clones from two donors (donor 1 and 2) for bovine 
PC, two hiPSC clones from two donors (donor 1 and 2) for HBPCT, two hiPSC clones from two donors (donor 1 and 2) for hAST, and three 
hiPSC clones from two donors (donor 1, and 2) for iPS_AC and yielded comparable results (eg, Figure S4). D, Immunofluorescence staining of 
EECM-BMEC-like cells cultured on 0.4 μm pore size Transwell filters. EECM-BMEC-like cells were seeded onto Transwell filters and either 
co-cultured with HBPCT (pericyte) or hiPSC-derived astrocytes over 6 days. Monoculture was used as a control. Junctions were stained for VE-
cadherin (red), claudin-5 (red), or occludin (red), and nuclei were stained with DAPI (blue). Representative data from donor 2 are shown. Each 
staining is representative of at least three independent differentiations performed on three distinct filters. Scale bars = 50 μm. E, The number of 
nuclei per pre-defined field of view (FOV) of EECM-BMEC-like cells grown on 0.4 μm pore size Transwell filters is shown. ImageJ software was 
used to automatically count the nuclei. F, EC shape was analyzed using circularity values (4 × π × area/perimeter2) calculated from VE-cadherin 
immunofluorescence images using ImageJ software. A value of 1.0 indicates a perfect circle. As the value approaches 0, it indicates an increasingly 
elongated shape of the cell. Each dot represents average circularity values of 10 randomly chosen cells/FOV. Data are shown as mean ± SD. 
Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison test. (**P < .01, ****P < .0001).
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conditions compared with monocultured EECM-BMEC-like 
cells (Figure 6A vs Figure 5A and Figure 6C; Figure S8). 
IL-1β-stimulation also showed similar effects on cell sur-
face ICAM-1 and VCAM-1 staining of SMLC co-cultured 
EECM-BMEC-like cells (Figure S9A). Interestingly, the 
SMLC co-culture could be replaced by providing CM from 
SMLCs to the abluminal side of EECM-BMEC-like cells 
monolayers (Figure 6B; Figure S8). Immunofluorescence 
staining of EECM-BMEC-like cells cultured in the pres-
ence of SMLC co-culture or SMLC-derived CM confirmed 
increased induction of VCAM-1 after cytokine stimulation 
(Figure 6D; Figure S9B).
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Considering the SMLC-enhanced cell surface expression 
of VCAM-1 on EECM-BMEC-like cells, we next asked if 
VCAM-1 would now play a role in Th1* cell adhesion to 
EECM-BMEC-like cells. As observed in the adhesion assays 
with monocultured EECM-BMEC-like cells, antibody-medi-
ated blocking of endothelial ICAM-1 or its Th1* ligand, β2-in-
tegrin, significantly reduced adhesion to SMLC-derived CM 
enhanced EECM-BMEC-like cells (Figure 6E). However, in 
key contrast to monocultured EECM-BMEC-like cells, anti-
body-mediated blocking of endothelial VCAM-1 in addition 
to its ligand, α4-integrin, on Th1* cells significantly de-
creased T-cell adhesion to EECM-BMEC-like cells indicat-
ing that SMLC-derived CM enhanced VCAM-1 expression 
on EECM-BMEC-like cells to levels of functional relevance.
Since smooth muscle cells can increase endothelial perme-
ability in the periphery,46 we also examined if SMLC-derived 
factors would impair barrier properties of the EECM-BMEC-
like cells. Although both co-culture of EECM-BMEC-like 
cells with SMLC- or SMLC-derived CM enhanced variabil-
ity of permeability measures, there was no significant effect 
on barrier characteristics of EECM-BMEC-like cells as de-
termined by TEER values or permeability to NaFl (Figure 
6G,H). Furthermore, co-culture of EECM-BMEC-like cells 
with SMLC did not change the junctional localization of VE-
cadherin, PECAM-1, ZO-1, claudin-5, or occludin (Figure 
6F). Taken together, SMLC-enhanced EECM-BMEC-like 
cells retain the barrier properties while displaying an opti-
mized cell adhesion molecule phenotype, thus making them 
a highly suitable model to study immune cell interactions 
with the human BBB in vitro. To verify their capability to 
fully support immune cell migration, we investigated the in-
teraction of human Th1* cells superfused over TNF-α/ IFN-γ 
stimulated EECM-BMEC-like cell monolayers under phys-
iological flow. In vitro live cell imaging demonstrated that 
Th1* cells arrest and polarize on EECM-BMEC-like cell 
monolayers. This was followed by Th1* crawling and prob-
ing prior to crossing the EECM-BMEC-like cell monolay-
ers (Figure 6I, Video S1), as observed by us previously on 
CD34+-derived BLECs.37 The EECM-BMEC-like cells thus 
allow for the observation of the individual steps of the multi-
step T-cell extravasation cascade across the BBB.
4 |  DISCUSSION
We set out to identify a human in vitro BBB model that 
is suitable for the study of BBB-immune cell interactions, 
which are important in CNS immune surveillance and neuro-
inflammatory diseases.3,4,47,48 Human BBB models have been 
generated from diverse sources, including primary or immor-
talized brain ECs10,49,50 and cord blood-derived endothelial 
progenitors.15,51 We focused, however, on models generated 
from hiPSCs, as they offer benefits in scalability and the 
potential for studying immune cell interactions in an autolo-
gous fashion. We first evaluated well-established protocols 
for generating hiPSC-derived BMEC-like cells via the UMM 
F I G U R E  5  Adhesion molecule phenotype of EECM-BMEC-like cells. A, Cell surface staining of EECM-BMEC-like cells for the adhesion 
molecules ICAM-1, ICAM-2, VCAM-1, P-selectin, E-selectin, CD99, and PECAM-1 was analyzed by flow cytometry. Isotype control, non-
stimulated (NS), and 16 h pro-inflammatory cytokine-stimulated condition (1 ng/mL TNF-α + 20 IU/mL IFN-γ) are represented in gray, blue, and 
red lines, respectively, in a histogram overlay. Representative data from donor 3 are shown. Three hiPSC clones from three donors (donor 1, 2, 
and 3) were used in this assay. B, The Δ geometric mean (MFI staining–MFI isotype) of cell surface adhesion molecules of EECM-BMEC-like 
cells were analyzed by flow cytometry. Displayed are the mean ∆MFI for each donor (donor 1: black, donor 2: red, and donor 3: blue). Mean ± 
S.D. from triplicate differentiations were used in a paired students t test to determine statistically significant changes upon stimulation (*P < .05, 
**P < .01). C, Immunofluorescence staining of EECM-BMEC-like cell monolayers grown to confluency in chamber slides for ICAM-1 (red), 
ICAM-2 (red), VCAM-1 (red), P-selectin (red), E-selectin (red), or CD99 (red) are shown. Nuclei were stained with DAPI (blue). Representative 
data from donor 2 are shown. NS and 0.1 ng/mL TNF-α + 2 IU/mL IFN-γ stimulated conditions are shown. Each staining is representative of at 
least three independent differentiations performed on three distinct chamber slides. Scale bars = 50 μm. D, The number of cell tracker-labeled Th1* 
cells adherent to non-stimulated (NS), 0.1 ng/mL IL-1β-, or 0.1 ng/mL TNF-α + 2 IU/mL IFN-γ stimulated EECM-BMEC-like cell monolayers 
derived from donor 2 were counted after 30 minutes of adhesion under static conditions. Adherent cells/FOV is the mean number of cells from two 
fields per well automatically counted using ImageJ. Data are shown as the mean ± SD of at least three individual differentiations each performed in 
triplicate. Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison test. (****P < .0001). E, The number of cell tracker-
labeled Th1* cells adherent to 0.1 ng/mL IL-1β stimulated EECM-BMEC-like cell monolayers were measured after 30 minutes of adhesion under 
static conditions. Adherent cells/FOV is the mean number of cells from two fields per well automatically counted using ImageJ. EECM-BMEC-
like cells derived from donor 2 were preincubated with either anti-human ICAM-1 (10 μg/mL, clone R6.5), anti-human VCAM-1 (10 μg/mL, 
polyclonal), or isotype controls for 30 minutes at 37°C. Th1* cells were pretreated with either mouse anti-human beta2 integrin (10 μg/mL, clone 
TS1/18), humanized anti-human α4 integrin IgG4 (10 μg/mL, Natalizumab), or isotype controls for 30 minutes at 37°C. Data are shown as the 
mean ± SD of a representative experiment of three individual differentiations each performed in at least triplicate. Statistical analysis: one-way 
ANOVA followed by Tukey’s multiple comparison test. (*P < .05, ****P < .0001). F, The numbers of Th1* cells adherent to 0.1 ng/mL IL-
1β stimulated EECM-BMEC-like cell monolayers derived from donor 2 under flow conditions were measured. Th1* cells were pretreated with 
either 10 μg/mL Natalizumab or isotype control for 30 minutes at 37°C. Data are shown as the mean ± SD of eight experiments in each condition. 
Three independently differentiated BMEC-like cell populations derived from donor 2 were used in this study. Statistical analysis: unpaired t test 
(*P < .05)
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and DMM.17,23 These and similar methods generate cells that 
achieve very high TEER, express known BBB solute and 
efflux transporters, and yield molecular permeabilities that 
correlate well with in vivo observations and these BMEC-
like cells are, therefore, well suited to study small and large 
molecule permeability.14,17,21,23,52–55 However, we found that 
BMEC-like cells differentiated by the UMM and DMM do 
not express all adhesion molecules shown to mediate the in-
teraction of immune cells with the BBB,4,8,48,56–58 and thus an 
alternative approach is required to examine such interactions. 
We, therefore, evaluated the immune cell adhesion mol-
ecule profile of naïve ECs differentiated from hiPSC-derived 
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EPCs,32 and observed basal or pro-inflammatory cytokine-
inducible expression of ICAM-1, ICAM-2, VCAM-1, 
E-selectin, P-selectin, CD99, and PECAM-1. However, these 
cells did not develop a passive barrier characteristic of the 
BBB. In contrast, after extended culture, the resulting cells 
displayed well-developed tight junctions, moderate TEER, 
and a flat cellular morphology and junctional architecture 
characteristic of primary BMECs. Importantly, after extended 
culture, the resulting cells retained an immune cell adhesion 
molecule profile similar to primary BMECs,26,27,59 and ex-
pressed ICAM-1, ICAM-2, E-selectin, P-selectin, CD99, 
and PECAM-1. Pro-inflammatory cytokine stimulation led 
to upregulation of ICAM-1 and P-selectin and induction 
of VCAM-1 that could be further enhanced by SMLC co-
culture or SMLC-derived CM treatment. Non-inflammatory 
expression of E-selectin on EECM-BMEC-like cells may be 
due to mechanisms involved in growth of EECM-BMEC-like 
cells as previously reported60 and must be considered when 
F I G U R E  6  Human iPSC-derived smooth muscle-like cells (SMLCs) or conditioned medium enhances VCAM-1 expression on EECM-
BMEC-like cells without impairing barrier properties. Cell surface staining of EECM-BMEC-like cells co-cultured with hiPSC-derived SMLCs 
(A) or conditioned medium from hiPSC-derived SMLC (B) for the adhesion molecules ICAM-1, ICAM-2, VCAM-1, P-selectin, E-selectin, CD99, 
and PECAM-1 was analyzed by flow cytometry. Isotype control, non-stimulated (NS), and 16 h pro-inflammatory cytokine-stimulated condition 
(1 ng/mL TNF-α + 20 IU/mL IFN-γ) are represented in gray, blue, and red lines, respectively, in a histogram overlay. Representative data from 
donor 3 are shown. Three hiPSC clones from three donors (donor 1, 2, and 3) were used in this assay (eg, Figure S8). C, The Δ geometric mean 
(MFI staining–MFI isotype) of cell surface VCAM-1 of EECM-BMEC-like cells were analyzed by flow cytometry. Monocultured EECM-BMEC-
like cells, EECM-BMEC-like cells co-cultured with hiPSC-derived SMLCs, or cultivated with conditioned medium from hiPSC-derived SMLC 
are shown. Each symbol (donor 1: black, donor 2: red, and donor 3: blue) shows the mean of at least three independent differentiations (co-culture 
condition, donor 1: n=3, donor 2: n= 4, and donor 3: n= 7). Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison 
test. (*P < .05). D, Immunofluorescence staining of EECM-BMEC-like cells derived from donor 3 grown to confluency in chamber slides using 
conditioned medium from hiPSC-derived SMLCs for ICAM-1 (red), ICAM-2 (red), VCAM-1 (red), P-selectin (red), E-selectin (red), or CD99 
(red) are shown. Nuclei were stained with DAPI (blue). NS and 16 h pro-inflammatory cytokine-stimulated condition (0.1 ng/mL TNF-α + 2 IU/
mL IFN-γ) are shown. Each staining is representative of at least three independent differentiations performed on three distinct chamber slides. 
Scale bars = 50 μm. E, The number of Th1* cells adherent to 16 h pro-inflammatory cytokine-stimulated (0.1 ng/mL TNF-α + 2 IU/mL IFN-γ) 
EECM-BMEC-like cell monolayers derived from donor 2 cultured in the presence of SMLC-derived conditioned medium, normalized to control 
condition was measured after 30 minutes of adhesion under static conditions. Adherent cells/FOV is the mean number of cells from two fields per 
well automatically counted using ImageJ. EECM-BMEC-like cells were preincubated with either anti-human ICAM-1 (10 μg/mL, clone R6.5), 
anti-human VCAM-1 (10 μg/mL, polyclonal), or isotype control for 30 minutes at 37°C. Th1* cells were pretreated with either anti-human beta2 
integrin (10 μg/mL, clone TS1/18), humanized anti-human α4 integrin IgG4 (10 μg/mL, Natalizumab), or isotype controls for 30 minutes at 37°C. 
Data are shown as the mean ± SD of three individual differentiations each performed in at least triplicates. Statistical analysis: one-way ANOVA 
followed by Tukey’s multiple comparison test (****P < .0001). F, Immunofluorescence staining on EECM-BMEC-like cells grown on 0.4 μm 
pore size Transwell filters co-cultured with SMLCs. Junctions were stained for VE-cadherin (red), PECAM-1 (red), ZO-1 (red), claudin-5 (red), 
or occludin (red), and nuclei were stained with DAPI (blue). Representative data from donor 2 is shown. Each staining is representative of at 
least three independent differentiations performed on three distinct filters. Five hiPSC clones from three donors (donor 1, 2, and 3) were used in 
this assay. Scale bars = 50 μm. G, TEER and (H) permeability of sodium fluorescein of EECM-BMEC-like cell monolayers derived from donor 
2 co-cultured with SMLCs or cultured in the presence of SMLC conditioned medium. EECM-BMEC-like cells were grown on 0.4 μm pore size 
Transwell filters in the presence of either SMLCs (pink) or conditioned medium from SMLCs in the lower chamber (abluminal side) (purple) for 
6 days. G, Plotted data are mean TEER values ± SD. H, Bars show the mean permeability coefficients (Pe) ± SD. (G, H) Data are representative 
of at least three independent differentiations with three filters per conditions. Three hiPSC clones from three donors (donor 1, 2, and 3) were used 
in this assay yielding comparable results. Human CD34+ cord blood stem cell-derived brain-like endothelial cells (BLECs, red) were used for a 
comparison to a previously developed human in vitro BBB model. I, In vitro live cell imaging of the Th1* cell/EECM-BMEC-like cells interactions 
under flow. A temporal snapshot illustrating that the different Th1* cell-EECM-BMEC-like cells interactions have been made with several frames 
taken from a video recorded with a 10× magnification. EECM-BMEC-like cells from donor 2 were cultured in cloning rings placed on collagen IV 
(10 μg/mL)-coated Ibidi μ-dishes at a density of 75,000/cm2. EECM-BMEC-like cells were stimulated with 0.1 ng/mL recombinant human TNF-α 
+ 2 IU/mL IFN-γ for 16 h at 37°C (5% CO2) diluted in conditioned medium from SMLC. Fluorescencently labeled Th1* cells were allowed to 
accumulate on the EECM-BMEC-like cell monolayer at a low flow rate of 0.1 dyne/cm2 for 4 min from the first frame after the first Th1* cells 
appear in the field of view (accumulation phase until 3 min 55 s). After the accumulation phase of precisely 3 min 55 sec, the flow rate was set to 
1.5 dyne/cm2 for 16 min (shear phase). Each row of images shows a different behavior (diapedesis (blue), crawling (orange), probing (pink)) of 
the Th1* cells with the EECM-BMEC-like cells. The red arrow shows the direction of flow and the time is displayed on the top left of each image 
(min:sec format). Time-lapse video showing Th1* cell interaction on EECM-BMEC-like cells is provided as Video S1. During the recording, 1 
picture is acquired every 5 second then the video is exported with a framerate of 30 images/second. The video is repeated four times, the first run 
shows the full-scale video, the second run is a zoom in of area highlighting T cells diapedesis (blue circles) and the third run is a zoom in crawling 
(orange circle) and diapedesis (blue circle), and the last run is a zoom in of one area highlighting crawling (orange circles) and probing (pink circle) 
events. The red arrow shows the direction of flow and the time is displayed on the top left of the video (min:sec format).
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using EECM-BMEC-like cells to study immune cell traffick-
ing across the non-inflamed BBB, which does not show con-
stitutive E-selectin expression in vivo.
We confirmed the functionality of ICAM-1 and VCAM-1 
in our model by employing blocking antibodies and observed 
reduced Th1* cell adhesion. While EECM-BMEC-like 
cells have weaker barrier properties than UMM- or DMM-
differentiated BMEC-like cells, they are similar to other 
human stem cell-derived models15,18,51 and primary mouse 
BMECs,61,62 and have stronger barrier properties than im-
mortalized human or rodent cell lines.10,50,63 EECM-BMEC-
like cells are similar to recently reported hiPSC-derived brain 
capillary-like endothelial cells (BCLECs)18 as both proceed 
through an EPC intermediate and develop a moderate TEER 
of ~60-80 Ω × cm2. However, in contrast to the work of Praça 
et al.18 we found that EECM-BMEC-like cells demonstrated 
pro-inflammatory cytokine-inducible expression of VCAM-
1, a prerequisite for studying immune cell interactions with 
the BBB.4,6 Taken together, while other hiPSC-derived BBB 
models are likely better suited to evaluate drug permeabil-
ity, drug efflux, and nutrient transport, EECM-BMEC-like 
cells have a robust adhesion molecule profile, functionally 
interact with Th1* cells, and have good paracellular barrier 
properties, making this model well suited to study immune 
cell-BBB interactions.
The EECM-BMEC-like cell differentiation protocol was 
adapted from an existing method to generate CD34+CD31+ 
EPCs from hiPSCs via small molecule activation of canon-
ical Wnt signaling.32 Prior work demonstrated that cultur-
ing these endothelial progenitors for 10 days in EGM-2, a 
widely used endothelial cell medium that contains serum 
and several growth factors (EGF, IGF, bFGF, and VEGF), 
yielded ECs with TNF⍺-inducible expression of ICAM-1 
and TEER of ~40 Ω × cm2.32 We, therefore, asked whether 
hECSR, a serum-free medium containing B-27 supplement 
and bFGF that has been previously used to culture BMEC-
like cells,17 would enhance the barrier phenotype of the re-
sulting ECs without compromising the robust immune cell 
adhesion molecule profile we observed. We found that after 
extended culture, the resulting ECs developed increased 
TEER of 60-80 Ω × cm2 and reduced NaFl permeability, 
phenotypes attributable both to improved EC monolayer 
purity and improvements to claudin-5 and occludin expres-
sion and junctional localization. Importantly, the presence 
of continuous localization of occludin to tight junctions, a 
hallmark of BBB endothelium,64 suggests specification of 
these naïve ECs to a barrier forming, BMEC-like pheno-
type. RA treatment or co-culture of the resulting EECM-
BMEC-like cells with pericytes or astrocytes did not lead 
to further improvements in barrier properties, and con-
versely, culturing these cells in serum- and mitogen-rich 
ECM-5 medium yielded markedly higher sodium fluo-
rescein permeability. In contrast, Praça et al.18 generated 
BCLECs from similar hiPSC-derived mesodermal endo-
thelial progenitors using EGM-2 medium, and found that 
VEGF, Wnt3a, and RA supplementation increased TEER 
from ~20 to 60 Ω × cm2, decreased Lucifer yellow perme-
ability, increased claudin-5 abundance, and increased ef-
flux transporter and solute carrier transcript expression.18 
Together, these observations suggest a strong dependence 
of endothelial barrier properties on basal cell culture 
medium, and that extended culture in minimal hECSR 
medium is sufficient to generate cells with a robust para-
cellular barrier in the absence of co-culture or additional 
exogenous factors. We note, however, that co-culture or 
supplementation of Wnts, RA, or other factors with known 
roles in BBB development65,66 could potentially improve 
aspects of BBB phenotype in EECM-BMEC-like cells, 
but the barrier properties, junctional architecture, and im-
mune cell adhesion molecule profile of the present model 
is well suited for the intended application. In fact, a major 
advantage of the EECM-BMEC-like model is the presence 
of functional VCAM-1, which plays a major role in the 
capture of T cells on endothelium via ⍺4β1 integrin bind-
ing.4,6 While recent work demonstrated TNF⍺-inducible 
expression of VCAM-1 in BMEC-like cells differentiated 
via the UMM, maintained under flow in collagen channels, 
and assayed after fixation and permeabilization,22 we did 
not observe cell surface VCAM-1 expression in UMM or 
DMM-differentiated BMEC-like cells. Furthermore, cyto-
kine-inducible expression of VCAM-1 in ECs differenti-
ated from hiPSC-derived endothelial progenitors has been 
variable, with some reports of positive67 and negative18,68 
results, and our monocultured EECM-BMEC-like cells 
only exhibited a modest response to inflammatory stimu-
lation. Given the importance of mural cells in endothelial 
function and previous observations that smooth muscle 
cell-EC interactions induce VCAM-1 in peripheral ECs,46 
we asked whether hiPSC-derived SMLCs could modulate 
VCAM-1 expression. Indeed, we found that co-culturing 
EECM-BMEC-like cells with hiPSC-derived SMLCs or 
SMLC-derived CM improved VCAM-1 inducibility on 
EECM-BMEC-like cells without significantly influencing 
barrier properties. Furthermore, VCAM-1 functionally con-
tributed to Th1* cell adhesion to SMLC-enhanced EECM-
BMEC-like cells as assessed using a VCAM-1 blocking 
antibody. Importantly, the SMLCs are a byproduct gener-
ated during the EECM-BMEC-like cell differentiation and 
as such, do not require independent differentiation of mul-
tiple cell types in parallel and are derived from the same 
hiPSC line as the EECM-BMEC-like cells, which should 
make this system readily applied to isogenic disease mod-
eling. Taken together, EECM-BMEC-like cells represent a 
novel hiPSC-derived in vitro model of the BBB possessing 
key molecular and functional attributes required to evalu-
ate the interactions of immune cells with the BBB.
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Cellular and molecular mechanisms mediating immune 
cell trafficking across the BBB have largely been studied in 
mouse models.4 Human in vitro BBB models have however 
been essential to confirm the translational importance of 
these mechanisms and verify novel therapeutic targets for 
inhibiting immune cell trafficking into the CNS in neuroin-
flammatory diseases in humans.12,31,62 Primary hBMECs 
have proven especially useful to study immune cell/BBB 
interactions and have allowed the identification of addi-
tional molecules expressed on the BBB like ALCAM,12,26 
MCAM,69 and ninjurin-1,70,71 which seem to contribute to 
the recruitment of pathogenic T cells and myeloid cells into 
the CNS in the context of neuroinflammation. However, pri-
mary human brain microvascular endothelial cells mainly 
originate from surgical specimens, limiting the ability to 
establish patient-derived in vitro BBB model from diseases 
where biopsy or surgery is not common. The contribution 
of BBB alterations mediating immune cell trafficking has 
been largely studied in autopsy brain samples. Indeed adhe-
sion molecules like ICAM-1, VCAM-1, ALCAM, MCAM, 
and ninjurin-1 were reported to be upregulated on brain 
endothelial cells in neuroinflammatory diseases such as 
multiple sclerosis.12,26,59,69–72 However, direct contribution 
of these endothelial adhesion molecules to disease patho-
genesis remains unknown since autopsy brain samples 
mainly reflect advanced stages of the disease and robust 
and reproducible functional assays using autopsy sam-
ples is quite difficult. Our novel EECM-BMEC-like cells, 
which possess proper adhesion molecules, open the field to 
study functional contributions of patient-derived brain en-
dothelium in mediating altered immune cell migration into 
the CNS. Furthermore, isolating immune cells from the 
very same donors will facilitate the study immune cell mi-
gration across the BBB in an entirely autologous fashion. 
This will eventually also allow for novel observations on 
how antigen-specific processes may contribute to immune 
cell/BBB interactions including BBB disruption or antigen 
presentation by brain endothelium in human neurological 
disorders.73
In conclusion, EECM-BMEC-like cells establish an in 
vitro BBB model that resembles, in morphology, molecu-
lar junctional architecture, diffusion barrier characteristics, 
and adhesion molecule profile, primary BMECs. Thus, this 
is the first model specifically adapted to study the role of 
the BBB in CNS immunity including immune cell migra-
tion across the BBB during CNS immune surveillance or 
inflammation. Additional molecular and cellular character-
ization of EECM-BMEC-like cells under non-stimulated 
and stimulated conditions will expand our understanding 
of how closely this novel model mimics neuroimmune 
conditions at the BBB ranging from CNS immune surveil-
lance to different neuroinflammatory disorders. Employing 
patient-derived or genetically modified hiPSCs in concert 
with the EECM-BMEC-like cell differentiation protocol 
will facilitate study of the contribution of BBB impair-
ment to CNS disorders ranging from multiple sclerosis to 
Alzheimer’s disease. Employing immune cells from the 
very same donors, will enable the unique opportunity to 
study immune cell interactions with the BBB in an autolo-
gous fashion.
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